<DOC>
	<DOCNO>NCT00170781</DOCNO>
	<brief_summary>This study design develop understanding efficacy safety use lumiracoxib treatment patient acute gout . This multi-center , double-blind , randomize , parallel group study compare single daily dose 400 mg lumiracoxib establish dose indomethacin 50 mg take three time day term efficacy</brief_summary>
	<brief_title>Efficacy Safety Lumiracoxib 400 mg Once Daily Acute Flares Gout</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Gouty</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Ambulatory cooperative male female patient least 18 year age With acute attack gout 4 joint less , diagnose clinically accord ACR 1977 classification criterion onset within last 48 hour prior evaluation . Where one joint involve , affect joint identify , study joint , baseline follow throughout study Who present Baseline acute pain intensity least moderate . With acute attack gout last 48 hour prior evaluation With polyarticular gout involve &gt; 4 joint With rheumatoid arthritis , infectious arthritis , pseudogout acute inflammatory arthritides . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Pain , acute gout , arthritis , cyclooxygenase-2 inhibitor , lumiracoxib , indomethacin</keyword>
</DOC>